U.S. markets close in 4 hours 27 minutes
  • S&P 500

    3,470.25
    -13.56 (-0.39%)
     
  • Dow 30

    28,515.21
    -91.10 (-0.32%)
     
  • Nasdaq

    11,647.11
    -24.44 (-0.21%)
     
  • Russell 2000

    1,643.90
    +10.09 (+0.62%)
     
  • Crude Oil

    41.09
    +0.21 (+0.51%)
     
  • Gold

    1,908.60
    +2.20 (+0.12%)
     
  • Silver

    24.65
    +0.24 (+0.98%)
     
  • EUR/USD

    1.1781
    +0.0054 (+0.46%)
     
  • 10-Yr Bond

    0.7720
    +0.0280 (+3.76%)
     
  • GBP/USD

    1.2985
    +0.0077 (+0.60%)
     
  • USD/JPY

    105.4580
    +0.0640 (+0.06%)
     
  • BTC-USD

    11,674.26
    +617.25 (+5.58%)
     
  • CMC Crypto 200

    238.25
    +4.58 (+1.96%)
     
  • FTSE 100

    5,904.66
    -14.92 (-0.25%)
     
  • Nikkei 225

    23,671.13
    +260.50 (+1.11%)
     

Fusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

·1 min read

HAMILTON, Ontario and BOSTON, Aug. 5, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that Chief Executive Officer John Valliant, Ph.D., will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 9:10am EDT.

(PRNewsfoto/Fusion Pharmaceuticals Inc.)
(PRNewsfoto/Fusion Pharmaceuticals Inc.)

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference-301106527.html

SOURCE Fusion Pharmaceuticals Inc.